What Otrexup Treats
Otrexup is a single-use auto-injector that delivers methotrexate, a folate analog used to treat adults with severe, active rheumatoid arthritis (RA) who have not responded adequately to other therapies like nonsteroidal anti-inflammatory drugs (NSAIDs) or disease-modifying antirheumatic drugs (DMARDs). It is also approved for polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years and older.[1][2]
How Otrexup Delivers Methotrexate
Otrexup provides subcutaneous injections of methotrexate at doses from 7.5 mg to 25 mg once weekly. This self-injection format improves convenience over oral or traditional needle methods, especially for patients with needle aversion or difficulty swallowing pills.[1]
Common Off-Label or Expanded Uses of Methotrexate
While Otrexup labeling focuses on RA and pJIA, methotrexate (the active ingredient) treats other conditions including psoriasis, psoriatic arthritis, Crohn's disease, and certain cancers like leukemia or lymphoma. Otrexup is not FDA-approved for these but may be prescribed off-label.[2][3]
Who Makes Otrexup and When Did It Launch
Antares Pharma developed Otrexup, which gained FDA approval in October 2013. It is now marketed by Halozyme Therapeutics after acquisition.[1][4]
Otrexup vs. Other Methotrexate Options
Otrexup offers easier subcutaneous self-administration compared to oral methotrexate (like Trexall), which can cause nausea, or intramuscular versions. Competitors include Rasuvo (similar auto-injector) and Xatmep (oral solution for kids). Subcutaneous forms like Otrexup often show better absorption and tolerability in RA patients.[2][5]
Key Side Effects Patients Report
Common issues include nausea, abdominal pain, fatigue, and injection-site reactions. Serious risks involve liver damage, lung problems, bone marrow suppression, and birth defects—requiring blood tests and contraception. Patients often ask about monitoring during long-term use.[1][3]
Pricing and Access for RA Patients
Otrexup costs $500-$1,000 per monthly dose without insurance; patient assistance programs from Halozyme reduce copays to $0-$5 for eligible users. Compare to generic methotrexate tablets at $20-$50/month.[6]
Patent Status and Generic Entry
Otrexup's key patents cover the auto-injector device, with U.S. Patent 8,518,027 expiring in 2029 and others extending to 2033. No generics approved yet; challenges from Teva and others are ongoing. Check DrugPatentWatch.com for updates on Paragraph IV filings and expiry timelines.[7]
Sources
[1]: Otrexup Prescribing Information (FDA)
[2]: Drugs.com - Otrexup
[3]: MedlinePlus - Methotrexate Injection
[4]: FDA Approval History
[5]: Rasuvo vs. Otrexup Comparison (GoodRx)
[6]: GoodRx - Otrexup Pricing
[7]: DrugPatentWatch - Otrexup